<- Go Home
Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Market Cap
$10.7M
Volume
265.5K
Cash and Equivalents
$3.1M
EBITDA
-$17.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$41.80
52 Week Low
$5.20
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
-$1.2M
Enterprise Value / EBITDA
0.07
Operating Income
-$17.5M
Return on Equity
231.18%
Return on Assets
-76.20
Cash and Short Term Investments
$14.0M
Debt
$2.2M
Equity
$8.8M
Revenue
N/A
Unlevered FCF
-$9.5M
Sector
Biotechnology
Category
N/A